Back to journals
Academic Journal

Journal of Clinical Psychiatry

23 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 23 psychedelic papers Blossom tracks from Journal of Clinical Psychiatry line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Journal of Clinical Psychiatry carry?

Sourced

Tracked papers by publication year; 1 earlier paper published before 2012. Click a year for the running total.

4papers published in 2022

+33% vs 2021

15 published by 2022

Browse papers→

Don't read as the journal's total output: only the 23 of 23 tracked psychedelic papers from Journal of Clinical Psychiatry with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Journal of Clinical Psychiatry publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
20
Suicidality
9
Anxiety Disorders
5
Schizophrenia
5
Neurocognitive Disorders
4
Addiction & Substance Use
3
Safety & Risk Management
3
Bipolar Disorder
2
Other
15

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Journal of Clinical Psychiatry cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ketamine
15
Esketamine
7
Psilocybin
3
5-MeO-DMT
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Journal of Clinical Psychiatry has 23 tracked papers indexed in Blossom (2006–2026) from 165 authors, most often covering Ketamine, Esketamine and Psilocybin, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Published Papers

Paywallindividual

Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial

This Phase IIa open-label proof-of-concept trial (n=10) investigated GH001, an inhaled formulation of 5-MeO-DMT (up to 6, 12, and 18 mg), in women with postpartum depression. All patients responded and achieved remission by day 8, with effects first seen two hours after the final dose. It was well tolerated, with headache the most common mild to moderate side effect.

Published
Journal
Journal of Clinical Psychiatry
Authors
Johnson, M., Baldo, P. A., Arbe, E., Brennan, B., Cohen, S. E., Doolin, K., Gann, W., Gregory, D., Keady, S., Kriger, K., MacIsaac, R., Ratcliffe, S., Rubinow, D. R., Svendsen, C. B., Terwey, T. H., Tully, D., Valcheva, V., Zantvoord, J. B., Deligiannidis, K. M.
Paywallindividual

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial

This open-label single-arm trial (n=20) found that a single 25 mg dose of psilocybin with psychological support was linked to rapid and lasting reductions in chronic suicidal thoughts and depression over 12 weeks. No serious adverse events were reported.

Published
Journal
Journal of Clinical Psychiatry
Authors
Vaart, A. V. D., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., Sackeim, H. A., Aaronson, S. T.
Paywallindividual

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial

This randomised trial (n=93) found that adding 16 weeks of cognitive behavioural therapy to esketamine was feasible for people with major depression and suicidal ideation, and it reduced suicidal thoughts and depression scores more than esketamine with usual care alone. No difference was seen in suicide-related events.

Published
Journal
Journal of Clinical Psychiatry
Authors
Wilkinson, S. T., Kitay, B. M., Macaluso, M., Santucci, M. C., Kumpf, K., Voghell, C., Astorino, L., Hershenberg, R., Martinez-Kaigi, V., Nowell, T., Thase, M. E., Sanacora, G., Rhee, T. G.
Paywallindividual

Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder

This one-year observational follow-up study (n=66) examined the long-term outcomes of psilocybin (25 mg, 10 mg, 1 mg; COMP360) in treatment-resistant depression (TRD). Median time to depressive relapse was longest in the 25 mg group (92 days) compared to 10 mg (83 days) and 1 mg (62 days), with most participants relapsing by week 12. A post hoc analysis of those entering the follow-up study (n=58) found a more pronounced difference, with the 25 mg group maintaining benefits for 189 days. Adverse events were minimal, with one case of mild suicidal ideation in the 1 mg group.

Published
Journal
Journal of Clinical Psychiatry
Authors
Goodwin, G. M., Nowakowska, A., Atli, M., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Marwood, L., Shabir, Z., Mistry, S., Stansfield, S. C., Teoh, E., Tsai, J., Young, M. B., Malievskaia, E.
Open Accessindividual

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression

This secondary analysis (n=321) of the ESCAPE-TRD trial compared work productivity loss (WPL) and related costs in patients with treatment-resistant depression (TRD) receiving esketamine nasal spray (56mg or 84mg) versus quetiapine (atypical antipsychotic) extended release, both combined with an oral antidepressant. By week 8, WPL decreased by 30.3% with esketamine and 17.3% with quetiapine, leading to a cost savings difference of $156 per week. By week 32, WPL reductions were 45.3% (esketamine) and 32.5% (quetiapine), with a weekly cost savings difference of $153.

Published
Journal
Journal of Clinical Psychiatry
Authors
Clemens, K., Pmhnp-Bc, A., Teeple, D., Zhdanava, M., Shah, A., Joshi, K., Buyze, J., Pilon, D., Bowrey, H. E., Godinov, Y.
Paywallindividual

Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression

This retrospective observational cohort study (n=966 esketamine initiators, n=39,219 controls) examines factors influencing esketamine initiation and continuation for treatment-resistant depression (TRD). Initiators resided closer to treatment centres, with initiation rates decreasing significantly with distance. Factors associated with increased initiation included posttraumatic stress disorder, suicidal ideation, and male sex, while Medicaid, substance use disorder, older age, and greater distance were associated with lower initiation rates.

Published
Journal
Journal of Clinical Psychiatry
Authors
Joshi, K., Liberman, J. N., Parab, P., Darer, J. D., Harding, L.

Quick Facts

Papers Indexed
23
h-Index
236
Open Access
No
Publisher
Physicians Postgraduate Press
Country
United States
Website
Visit